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Abstract
Introduction: Our previous work showed higher tumour necrosis factor (TNF)-a levels in patients with chronic low
back pain (cLBP) compared to healthy controls. However, patients with depression as a comorbidity did not have
higher TNF-a levels in comparison to patients without depression. In this study we investigated the influence of
depression on therapy outcomes such as TNF-a serum levels, pain intensity and back function in patients with
cLBP. Our hypothesis was that patients with both cLBP and depression benefit no less than patients with cLBP
alone from the multidisciplinary pain therapy.
Methods: A total of 58 patients with cLBP alone or with both cLBP and depression were age- and sex-matched
with 29 healthy controls. Serum concentrations of TNF-a were assayed at the beginning of the study (T0) and 10
days (T1), 21 days (T2), and 180 days (T3) later. The clinical outcomes such as pain intensity, as well as back
function, sleep, exercise, alcohol and nicotine consumption were documented. In the first three weeks, all patients
underwent multidisciplinary therapy based upon biological, psychological, physical and psychosocial components.
Results: Over the whole course there were no differences in TNF-a level between cLBP patients with and without
depression. At T0, both cLBP patients with (cLBP+DE) and without (cLBP) depression showed significantly higher
TNF-a serum levels (P = 0.002 for cLBP+DE, P = 0.004 for cLBP) than healthy controls (HC) that normalized after 10
days of therapy and remained similar to healthy controls. During the follow-up, the depression scales were
normalised and pain intensity was significantly reduced. Both evidences processed parallel to the reduction of TNF-
a levels, which correlates neither with depression score nor with pain intensity at any time point.
Conclusions: Depression as a comorbidity to chronic low back pain did not influence the serum TNF-a level in
the course of six months, but seemed to affect the success of therapy. cLBP patients with comorbidity of
depression benefit from multidisciplinary pain therapy not only to the same extent but also to a greater degree
than cLBP patients without depression.
Introduction
Patients with chronic pain have mostly additional psy-
chiatric diseases. The range lists from the most to the
fewest constellation include the affective diseases
(depression), psychopharmaca associated diseases, soma-
toforme and anxiety disorders which are more frequent
in chronic pain patients than in healthy subjects [1,2].
The Canadian National Population Health Survey found
that the incidence of a major depression was doubled in
patients with long-term back diseases [3]. Diseases with
long-term persistent pain have higher risks of depression
[4,5]. cLBP patients with depressive symptoms exhibit
higher pain intensity, considerable impairment due to
pain [6] and more passive avoidance behaviour than
patients without comorbidity [7]. Depression is a risk
factor for development and maintenance of chronic pain
and long-term disturbance inclusive working place lost
[8]. And depression seems to be a predictor for disabil-
ity of chronic pain patients [9] and is associated with
worse functional ability and more disorders due to pain
[10]. The costs of medical treatment for cLBP patients
with depression was found to be 2.8 times higher than
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nomic cost of depressive disorders is higher in the pre-
sence of coexisting pain [12]. Summarized, depression
and pain share the same neurotransmitter and pathways
and influence each other, increase their prevalence and
affect the treatment/treatment successes of one another
[13]. Therefore, the accompanying depression should be
recognized early and taken into account in the treat-
ment strategy for chronic pain [14-17].
To date, however, pain and depression have been con-
sidered as separate entities and therefore treated in iso-
lation. The number of therapy resistant patients with
chronic pain who could not be helped by the conven-
tional therapy and, therefore, still looking for further
medical help, is calculated at about 400.000 to 700.000
in Germany. The reasons for the breakdown of conven-
tional therapy are isolated therapy of assumed causal
causes or mostly only drug therapy or passive treatment
strategies [18] without consideration of psychopharma-
cological knowledge and the common ground of pain
and depression.
Over the past 10 years we have performed in our
clinic a multidisciplinary pain therapy which was based
on biological, psychological, physical and psychosocial
components. This therapy comprised six-hour sessions
on five days per week for three weeks, giving a total of
90 hours [19]. The goal of this therapy is to restore the
physical and psychosocial abilities of the patients, to
expand their knowledge of back protection techniques
a n dp r o t e c t i v eb e h a v i o u r ,t oi m p r o v ep o s i t i v es k i l l sf o r
individual coping and emotional controls, and to
increase the patient’s activity levels when they return to
the workplace. It integrates physical exercises, ergo-
nomic training, psychotherapy, patient education, beha-
vioural therapy and workplace-based interventions in
individual therapy and in group sessions.
Our previous work showed great successes with the
multidisciplinary pain therapy [20,21], which also
worked on reduction of elevated serum levels of TNF-a
in patients with cLBP [22] and fibromyalgia[19].
We wonder whether the changes in TNF-a level could
influence the development of depressive symptoms, if
we follow up for six months the course of TNF-a level,
depression scores parallel to pain intensity. The hypoth-
eses of this prospective, longitudinal study were 1)
patients with both cLBP and depression benefit to the
same degree from the multidisciplinary pain therapy; 2)
the changes of TNF-a level are associated with develop-
ment of depressive symptoms.
Materials and methods
Subjects
All participants gave informed consent, and the study
was approved by the local ethics committee of the
University of Heidelberg, Germany. Participants were
consecutively recruited from the Department of Ortho-
paedic Surgery of the University of Heidelberg. Each
group of 29 patients with chronic low back pain (cLBP)
alone or cLBP together with depression (cLBP+DE)
were matched with 29 healthy controls (HC) by age and
sex. This prospective longitudinal study was conducted
over a period of six months (Table 1).
The inclusion criterion for pain was cLBP as the main
symptom, defined as disabling pain of at least six months’
duration that led to the patient being on sick leave for at
least six weeks. Patients with other pain locations as their
main symptom and patients with multiple major pain
locations were excluded from this study.
The inclusion criteria for the diagnosis “depression”
were: (i) an ICD-10 diagnosis of a current and an at
least moderate depressive episode; (ii) a minimum CES-
D score of 25.
Exclusion criteria in patients and controls were:
tumour disease (diagnosis from history and by radio-
graphic/MRI examination); trauma/fracture (history and
radiographic examination); inflammatory systemic dis-
ease or infection, for example, spondylodiscitis (blood
count and radiographic evaluation/MRI); nucleus pulpo-
sus prolapse with corresponding radicular pain (clinical
examination, MRI); structural pathology of the lumbar
spine, for example, spinal stenosis or spondylolisthesis
(radiographic evaluation/MRI and clinical examination);
rheumatological disease; serious cardiopulmonary, vas-
cular or other internal medical conditions; any sensori-
m o t o ra n d / o rn e u r o l o g i c a ld e f i c i t si nt h el o w e r
extremity (clinical examination); spinal surgery in the
year before admission to multidisciplinary therapy;
radiographically apparent degenerative changes in the
lumbar spine (grade II or above according to the Kellg-
ren and Lawrence classification,1957 [23]; medication
that may influence TNF-a l e v e l( f o re x a m p l e ,o r a lo r
local corticosteroids, aspirin, anti-TNF-a therapy); psy-
chiatric disorder.
Multidisciplinary pain therapy (MDPT)
Patients with cLBP or cLBP+DE underwent an in-
patient course of multidisciplinary therapy with biologi-
cal, psychological, physical and psychosocial compo-
nents. This comprised six-hour sessions on five days per
week for three weeks, giving a total of 90 hours [19].
The goal of this therapy is to restore the physical and
psychosocial abilities of the patients, to expand their
knowledge of back protection techniques and protective
behaviour, to improve positive skills for individual cop-
ing and emotional controls, and to increase the patient’s
activity levels at their return to the workplace. It inte-
grates physical exercises, ergonomic training, psy-
chotherapy, patient education, behavioural therapy and
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in group sessions.
After completion of this treatment program, the
patients were discharged without further interventions
by the hospital. They were allowed to contact the
p h y s i c i a nw h oh a dr e f e r r e dt h e mf o rt h e r a p y ,b u tt h e y
were advised to manage similar further pain episodes on
their own without immediately contacting a physician.
Further utilization of medical services after completion
of the therapy program was not monitored.
Table 1 Clinical and psychosocial data of all subjects
cLBP+DE
(n = 29)
cLBP
(n = 29)
Mann-Whitney-U-Test
Sex: female/male (number) 17/12 17/12 P > 0.05
Age: mean (range) (years) 45.3 (20 to 69) 44.7 (24 to 68) P > 0.05
Body mass index (BMI): 25.1 (18.9 to 37.4) 24.2 (17.7 to 33.3) P > 0.05
Sleep (24 h)
Day 0 = T0 5.25 6.08 P > 0.05
Day 21 = T2 5.4 5.62 P > 0.05
Day 180 = T3 5.95 6.11 P > 0.05
Exercise (24 h)
Day 0 = T0 5.67 ± 5.09 5.28 ± 3.95 P > 0.05
Day 21 = T2 4.87 ± 5.28 6.27 ± 6.16 P > 0.05
Day 180 = T3 5.95 ± 5.60 5.18 ± 4.05 P > 0.05
pain 24 h: mean (VAS 0 to 10)
Day 0 = T0 6.30 ± 1.89 5.13 ± 2.30 P > 0.05
Day 21 = T2 4.18 ± 2.04 3.75 ± 2.44 P > 0.05
Day 180 = T3 3.55 ± 2.63 4.44 ± 3.25 P > 0.05
pain 7d: mean (VAS 0 to 10)
Day 0 = T0 6.29 ± 1.58 5.19 ± 2.27 P > 0.05
Day 21 = T2 4.61 ± 1.65 4.19 ± 2.50 P > 0.05
Day 180 = T3 3.90 ± 2.57 4.65 ± 2.86 P > 0.05
CES-D: (score)
Day 0 = T0 32.81 ± 9.38 12.68 ± 6.64 P < 0.001*
Day 21 = T2 20.00 ± 11.20 9.00 ± 7.73 P < 0.001*
Day 180 = T3 19.50 ± 10.87 13.53 ± 10.74 P > 0.05
back function (R&M):
Day 0 = T0 13.77 ± 5.26 10.19 ± 5.65 P = 0.022**
Day 21 = T2 9.48 ± 6.31 7.87 ± 5.08 P > 0.05
SF-36 PCS score
Day 0 = T0 32.73 ± 7.97 31.24 ± 10.61 P > 0.05
Day 21 = T2 36.41 ± 7.76 35.93 ± 9.49 P > 0.05
Day 180 = T3 37.75 ± 7.80 41.37 ± 11.97 P > 0.05
SF-36 MCS score
Day 0 = T0 28.95 ± 10.01 47.97 ± 6.26 P < 0.001*
Day 21 = T2 34.45 ± .66 52.08 ± 7.41 P < 0.001*
Day 180 = T3 45.77 ± 9,51 46.64 ± 11.24 P > 0.05
Alcohol consumption (24 h)
Day 0 = T0 16% 19% P > 0.05
Day 21 = T2 26% 8% P > 0.05
Day 180 = T3 52% 19% P = 0.03**
Nicotine consumption (24 h)
Day 0 = T0 42% 23% P > 0.05
Day 21 = T2 48% 29% P > 0.05
Day 180 = T3 47% 17% P = 0.041**
CES-D, German version of the Centre for Epidemiological Studies; cLBP, chronic unspecific low back pain; cLBP+DE, chronic unspecific low back pain and
comorbidity of depression; MCS, Mental Composite Scale; pain 24 h, average pain in the last 24 hours; pain 7 d, average pain in the last seven days; PCS,
physical Composite Scale; R&M, Roland & Morris Disability Questionnaire; SF-36, 36-item short form health survey; VAS, visual analogue scale. *: still significant
after adjustment by Bonferroni-correction (< 0.005); **: not more significant after adjustment by Bonferroni-correction (> 0.005)
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At study entry, the initial evaluation included clinical
and radiographic examination and also MRI of the lum-
bar spine in all patients of the entire study, and blood
count in all patients and controls. Each patient and con-
trol was evaluated at four fixed time points with investi-
gations, including analysis of blood samples. The
specific time points were the beginning of the study
(T0), Day 10 (T1), Day 21 (T2) and finally at six months
(T3) follow-up. Patients were additionally evaluated by
standardized questionnaires and physical examinations
at these time points.
Pain
Average pain intensity of all patients was determined
from a visual analogue scale recording from 0 (no pain)
to 10 (severe pain) during the last 24 hours and last
week.
Back function
Measures of pain-related disability was assessed by using
the Roland and Morris questionnaire [24], which is a
self-administered questionnaire consisting of 24 item
chosen to reflect varied activities of daily living. An item
receives a score of 1 if it is checked as applicable by the
respondent and a score of 0 if it is not marked. Accord-
ingly, total scores can vary from 0 (no disability) to 24
(severe disability).
Depression
The CES-D is a well-established self-reporting instru-
ment to assess the level of depression with 20 items and
a potential overall score of 0 to 60. It has high specificity
(94%) for the identification of acute depression if a score
of at least 23 points is reached and the correlation coef-
ficient to other instruments for measuring depression,
such as the Hamilton Depression Scale, is acceptable
(r = 0.49) and increases with recovery from depression
(r = 0.86) [25].
To identify other confounding factors, at each time
point the patients filled in this standardized question-
naire about sleep duration, alcohol and nicotine con-
sumption, exercise and SF-36 questionnaire.
The SF-36 questionnaire was originally developed for
the Rand Corporation’s Health Insurance Experiment
[26,27]. It is a self-administered, 36-item questionnaire
that measures health-related functions in eight domains
represented by eight scales. These generate two compo-
site scales: PF = Physical Functioning, RP = Role Physi-
cal, BP = Bodily Pain, GH = General Health > PCS =
Physical Composite Scale; VT = Vitality, SF = Social
Functioning, RE = Role Emotional, MH = Mental Health
> MCS = Mental Composite Scale. After summing the
Likert-scaled items in the SF-36, each scale was then
standardized so that the scores ranged from 0 (lowest
level of functioning) to 100 (highest level).
To identify confounding factors of medication, drug
intake in the two groups was studied accordingly to the
ATC Classification System (ATC System).
Determination of cytokine levels in serum
At the given time points, venous blood was taken from
the cubital vein between 8 a.m. and 9 a.m. Blood sam-
ples were centrifuged at 2,000 rpm at 4°C within 30
minutes of withdrawal and serum was stored at -80°C.
TNF-a serum levels were analysed in duplicate using a
Bio-Plex cytokine assay (Bio-Rad Laboratories, Munich,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Median fluorescence intensity (MFI) of standards and
patient samples were determined. Using the Bio-Plex
Manager software, serum levels of TNF-a were deduced
from the standard curve. The intra-assay coefficient of
variation was 5 to 10%.
Statistical analysis
In case of significant results, single t-tests with Bonfer-
roni correction and a P <0 . 0 5w a su s e d .A N O V At e s t s
were used for analysis of repeated measures. Correla-
tions between the individual groups and cytokines were
investigated using the c
2 test, Fisher’s exact test, and the
phi coefficient. Drug intake was analysed as captured/
non-captured without considering the dose. The non-
parametric McNemar test was used to identify signifi-
cant changes in medication during the six-month study
period. Correlations of medication according to the
ATC System with cytokine levels were calculated using
the c
2 test, Fisher’s exact test, and the phi coefficient.
P-values below 0.05 were considered statistically signifi-
cant; those below 0.01, highly significant. The data were
analysed using SPSS 15.0 software (SPSS, Chicago, IL,
USA).
Results
TNF-a serum levels
At T0 both patient groups, with and without comorbid
depression, showed significantly higher TNF-a serum
levels than healthy controls (P = 0.002 for cLBP+DE, P
= 0.004 for cLBP). At T1, T2 and T3, no differences in
TNF-a serum level were found between patient group
and the healthy controls (P = n.s.). No differences in
TNF-a levels between the cLBP+DE group and the
cLBP group were seen at any time (Figure 1).
The TNF-a levels in both back pain groups decreased
significantly between T0 and T1 (both P <0 . 0 0 1 ) .F r o m
T1 to T2, only the cLBP+DE group showed a significant
increase (P = 0.004) in TNF-a levels; in the cLBP group,
TNF-a levels were unchanged. From T2 to T3, TNF-a
levels in both cLBP groups decreased significantly
(P = 0.023 for cLBP+DE, P = 0.038 for cLBP). At T3,
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groups compared to the level at T0 (P =0 . 0 3 7f o rL B P
+DE, P = 0.009 for cLBP) (Figure 1).
Depression scores
At all time points the CES-D scores were higher in the
cLBP+DE group than in the cLBP group. There were
significant differences between the two groups at T0
and T2 (P < 0.001 in both cases) but not at T3. At T3
(six months after therapy) the CES-D scores of the two
groups were similar (Table 1). The mean CES-D scores
of both groups decreased significantly from T0 to T2
(cLBP+DE: P < 0.001, cLBP: P = 0.009). Between T2
and T3 there were no significant changes. Over the total
study period of six months only the comorbid cLBP+DE
group showed a significant decrease (P < 0.001) (Table
2, Figure 2).
Pain intensity (last 24 hours and last week, numeric
rating scale)
Regarding pain intensity of the last 24 hours and the last
week both groups did not differ of each other at all time
points. At T0 and T2 the comorbid cLBP+DE group
showed a higher mean of pain whereas at T3 cLBP
group displayed a greater intensity (Table 1). Patients of
both groups reported significantly less pain at T2 than
at T0 (pain 24 h: cLBP+DE and cLBP: P <0 . 0 0 1 ,p a i n7
d: cLBP+DE: P < 0.001, cLBP: P = 0.049). The cLBP+DE
group still showed this significant difference in both
pain intensities after six months at T3 (P < 0.001), at
w h i c ht i m et h e yd e m o n s t r a t e da4 9 %( 2 4h )a n d4 1 %
(7 d) amelioration of perceived pain compared to T0,
while patients with only cLBP improved their perceived
pain only 15% (24 h) and 11% (7 d) in the total study
period (each n.s.) (Table 2, Figure 2).
Back function (Roland and Morris Disability
Questionnaire)
Patients with both cLBP and depression (cLBP+DE)
showed worse back function than patients with cLBP
alone at T0 (P = 0.022), but not at T2. Three weeks
after initiation of the therapy both groups of patients
displayed improvements in back function: 35% in cLBP
+DE and 25% in cLBP. These changes were significant
in both groups (P < 0.001 for cLBP+DE, P =0 . 0 0 1f o r
cLBP) (Table 1).
Habits (sleep, exercise, alcohol and nicotine consumption)
There were no differences in reported sleep duration (in
the past 24 hours) or alcohol and nicotine consumption
Figure 1 Serum levels of pro-inflammatory cytokine TNF-a (pg/ml, median) in patients with cLBP and HC during 6 months’ follow-up.
The serum level of TNF-a was measured using the Bio-Plex cytokine assay (Bio-Lab, Munich, Germany). The y-axis shows the median values of
TNF-a serum levels (pg/ml). The Mann-Whitney-Test showed that serum levels of TNF-a of cLBP patients both with and without depression (DE)
were significantly higher than those of healthy controls at day 0, but not at days 10, 21 and 180. **: P < 0.01, differences between patient
groups and healthy controls; ###: P < 0.001, ##: P < 0.01, #: P < 0.05, decrease between T0 and T1 or T0 and T3. cLBP, chronic low back pain; HC,
healthy controls.
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alone at the beginning of the study period, or between
admission and discharge in cLBP+DE. However, at the
end of the study a higher proportion of the formerly
depressive cLBP patients reported consumption of alco-
hol (cLBP+DE 52%, cLBP 19%; P = 0.037) and nicotine
(cLBP+DE 48%, cLBP 17%; P = 0.041) in the previous
24 hours (Table 2). The two patient groups did not dif-
fer in exercise level of the previous 24 hours at any time
point (Table 1).
SF-36 physical Composite Scale (PCS) and Mental
Composite Scale (MCS)
The PCS scores of both patient groups did not differ at
any time points. Compared to T0, cLBP patients dis-
played an amelioration of 13% (P = 0.006) at T2 and of
25% at T3 (P = 0.01), while cLBP+DE patients improved
the PCS for 8% at T2 (P > 0.05) and 17% at T3 (P =
0.036) respectively.
The MCS scores was significantly higher in cLBP
group than cLBP+DE at T0 (P < 0.001) and T2 (P <
0.001) but not at T3. Compared to T0, cLBP+DE
patients improved the MCS for 25% at T2 (P < 0.001)
and 57% at T3 (P = 0.002) respectively, while cLBP
patients displayed an amelioration of 11% at T2 (P =
0.001) and of 4% at T3 (P > 0.05).
Medication
Daily intake of medication
There was no significant difference in medication (inclu-
sive antidepressants) intake between the two groups at
any time point, except that patients in the cLBP+DE
group were taking significantly more NSAIDs (M01A)
than patients with cLBP alone at T0 (P = 0.037).
Intake of medication in the past 24 hours
No significant differences were found between the two
groups. Comparing T0 and T3, significant reductions in
daily intake of analgesics from 28% to 3% (N02, P =
0.039) and of NSAIDs from 28% to 7% (M01A, P =
0.031) were observed in the cLBP+DE group and of
opioids (N02A, P = 0.031) from 28% to 7% in the cLBP
group.
Correlation between TNF-a serum level and confounding
factors
No correlation was found between TNF-a serum level
and age, sex, BMI, CES-D score or back function. The
single correlation between TNF-a serum level and pain
i nt h ep r e v i o u sw e e kw a sf o u n da tT 3( P =0 . 0 4 6 ;p h i
coefficient = 0.490) in the comorbid depression group
(cLBP+DE), but not in the cLBP group without depres-
sion. A negative correlation between TNF-a serum level
and intake of analgesics was found at T0 in cLBP+DE
(P =0 . 0 2 7 ,S=–0.411) and a positive correlation
between TNF-a serum level and NSAIDs at T3 in cLBP
(P = 0.022, S = .486). But all these significances disap-
peared after adjustment by Bonferroni-correction.
Discussion
To our knowledge, this is the first study which investi-
gates the co-existence of pain and depression regarding
circulating TNF-a in a longitudinal design. As we know,
t h ep r o - i n f l a m m a t o r yc y t o k i n eT N F - a plays a role both
in pain and depression. Both patients with depressive
symptoms and patients with pain disorders often display
enhanced cytokine levels. A recent review pointed out
that the pathophysiologies of pain and depression may
overlap in many respects [28]. It has been demonstrated
that several brain regions are implicated in both major
depressive disorder (MDD) and pain. For example, the
insular cortex [29,30], the prefrontal cortex [31,32], the
Table 2 Changes of TNF-a levels and clinical parameters
during 6-months follow-up
cLBP+DE
(n = 29)
cLBP
(n = 29)
TNF-a levels T0/T1 ↓*** ↓***
T0/T2 n.s. n.s.
T0/T3 ↓* ↓**
CES-D scores T0/T1 n.c. n.c.
T0/T2 ↓*** 39% ↓** 31%
T0/T3 ↓*** 43% n.s. (3% ↓)
Pain 24 h T0/T1 n.c. n.c.
T0/T2 ↓*** 36% ↓*** 26%
T0/T3 ↓*** 49% n.s. (15% ↓)
Pain 7 d T0/T1 n.c. n.c.
T0/T2 ↓*** 31% ↓*** 41%
T0/T3 ↓* 17% n.s. (11% ↓)
R&M scores T0/T1 n.c. n.c.
T0/T2 ↓*** 35% ↓** 25%
T0/T3 n.c. n.c.
Exercise 24 h T0/T1 n.c. n.c.
T0/T2 n.s. (10% ↓) n.s. (19% ↑)
T0/T3 n.s. (17% ↑) n.s. (13% ↑)
SF-36 PCS scale T0/T1 n.c. n.c.
T0/T2 n.s. (8% ↑) ↑* 17%
T0/T3 ↑** 13% ↑* 25%
SF-36 MCS scale T0/T1 n.c. n.c.
T0/T2 ↑*** 25% ↑**11%
T0/T3 ↑** 57% n.s. (4% ↑)
↑, increase; ↓, decrease; CES-D, German version of the Centre for
Epidemiological Studies Depression Scale; cLBP, chronic unspecific low back
pain; cLBP+DE, chronic unspecific low back pain and comorbidity of
depression; MCS, mental Composite Scale; n.c., not collected; n.s., not
significant; PCS, Physical Composite Scale; SF-36, 36-item short form health
survey; T0/T1, difference between Day 0 and Day 10; T0/T2, difference
between Day 0 and Day 21; T0/T3, difference between Day 0 and Day 180;
TNF-a, tumour necrosis factor- alpha; VAS, visual analogue scale. *: P < 0.05;
**: P < 0.01; ***: P < 0.001
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hippocampus [35-37] are activated and/or altered in
response to both depression and pain. Moreover, Robin-
son [28] verified that shared neurocircuits and neuro-
chemicals play an important role connecting the
pathophysiologies of depression and pain disorders.
However, the mechanisms of the interaction between
cytokine, pain and depression are so far not clarified.
Few studies address this focus, up to now.
In the current study, we tried to find out some evi-
dence for the connection between TNF-a,p a i na n d
depressive symptoms. From the current study we
learned that patients with chronic low back pain dis-
played a chronic systemic inflammation, independent
from the presence of depression or not. Patients with
both cLBP and depressive symptoms had worse back
function and mental composite scale than those without
depression at the beginning but not at the end of the
study (Table 1). Otherwise, they did not differ from
each other during the whole course, regarding TNF-a
level, exercise activity, physical composite scale, sleep
duration and pain intensity (Table 1).
Besides, we found from this study that MDPT some-
how managed the decline of circulation TNF-a first,
and subsequently the pain and depression impairment.
Patients with both cLBP and depressive symptoms
improved more in their clinical parameters regarding
CES-D scores, pain intensity, R&M scores, MCS scale
than those without depression (Table 2) who just gained
a greater reduction in TNF-a level and PCS scale. The
outcome of this is the following explanation of our find-
ings (Figure 3):
Supposedly due to exercise therapy within MDPT the
circulating level of TNF-a decreased and the following
improvement in clinical parameters three weeks after is
a result of TNF-a reduction.
Due to intensive psychotherapy or synergetic effects of
exercise and psychotherapy, the depression scores
decreased and subjective pain perception, back function,
mental composite scale were improved, while TNF-a
Figure 2 Course of TNF-a serum level, pain intensity and depression score during six months’ follow-up. The two patient groups
showed no differences in TNF-a serum level or pain intensity at any time point. Patients with depression showed significantly higher CES-D
values than those without depression at t0 (P < 0.001) and t2 (P < 0.001), but not at t3 (P > 0.05). All three parameters were significantly lower
at t2 and t3 than at t0, with the exception of CES-D at t3 in patients with isolated cLBP. n.c. = not collected. *: differences between patient
groups (*** = P < 0.001); #: comparison of T1, T2 and T3 each vs T0 (### = P < 0.001, ## = P < 0.01; # = P < 0.05).
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healthy controls.
Six months after the therapy, we noticed that para-
meters related to psychological elements such as depres-
sive scores, mental composite scales, physical composite
scales and even subjective visual analogue scores of pain
stayed constantly and strongly improved in both patient
groups from the beginning of the therapy. The interest-
ing and, maybe also groundbreaking, fact from this
study was that patients with both pain and depression
showed stronger improvement in psychological elements
such as depression scores, pain intensity, back function
and mental composite scales while patients with only
cLBP showed more improvement in physical elements
such as physical composite scales. The course of TNF-a
serum level was similar in both groups but the decrease
over the total study period was higher in patients with
only cLBP. This may point out that the pain in cLBP
patients with depression is attributable to somatic symp-
toms of depression rather than primary pain, because
patients with a comorbidity of depression respond more
favourably to an intensive intervention involving signifi-
cant interpersonal contact and support as they did dur-
ing psychological elements of MDPT. That is why the
improvement in pain was greater in the comorbid cLBP
+DE group.
In the current study, the reduction of elevated TNF-a
serum levels in both cLBP patient groups after MDPT
may be considered as a psychoneuroimmunological cor-
relate to the physical therapy and psychotherapy within
the framework of MDPT. We guessed that one factor of
MDPT (physical exercises, ergonomic training, psy-
chotherapy, patient education, behavioural therapy and
workplace-based interventions in individual therapy and
in group sessions) or more factors together play a role
in the normalization of TNF-a serum level so that the
synergistic effect of all elements trigger the reduction of
depressive and pain scores. The mechanisms can be
explained as follows:
In regard to exercise therapy, it is known that exercise
modulates the inflammatory response through neuroen-
docrine mechanisms. All exercise-induced changes in
the innate/inflammatory response are mediated by stress
hormones, mainly gluococorticoids and catecholamines
[38,39]. Since the cLBP patients displayed chronic
inflammation and seem to be associated with a deregu-
lation of the inflammatory response state [22,40], which
could cause an unbalanced hypothalamic-pituitary-adre-
nal axis and sympathetic nervous system activity, it
could be plausible that exercise therapies could work at
this level in cLBP patients.
In terms of psychotherapy, to date, randomized con-
trolled trials have supported the efficacy of cognitive
behavioural treatment (CBT) in treating both major
depression [41] and pain disorders [42,43]. For the treat-
ment of major depressive disorders (MDD), the combi-
nation of pharmacotherapy with CBT is optimal in
some patient populations, such as chronic depression
[44] and chronic pain conditions [42,45]. A meta-
analysis of psychotherapeutic approaches for chronic
lower back pain showed improvements of pain and
depression in response to CBT and self-regulatory treat-
ment [46]. It seems that the multidisciplinary nature of
the pain therapy may have an especially persistent posi-
tive impact on health-related quality of life in the pre-
sence of manifest depression. In the present study, the
significant difference between the two back pain groups
in the mental composite scale (MCS) can be explained
by the significant moderator influence of the variable of
depressivity. The mean value for MCS was significantly
lower in the group cLBP+DE than in the group cLBP at
t h ef i r s tt w ot i m ep o i n t s( T a b l e1 ) .T h eM C Sv a l u eo f
the comorbid back pain group was lower than in the
German reference sample at all time points, whereas
Exercise Therapy 
TNF- ↓, PCS↑
Multidisciplinary 
Pain Therapy 
Exercise Therapy 
(both cLBP groups) 
Psychotherapy 
(both cLBP groups, main impact for cLBP+DE)
CES-D↓, VAS↓, MCS ↓, 
Improvement in depressive 
Symptoms and Pain
Figure 3 The explanation of the current findings. CES-D, German version of the Centre for Epidemiological Studies Depression Scale; cLBP,
chronic low back pain; DE, depression; MCS, mental Composite Scale; PCS, physical Composite Scale; TNF-a: tumour-necrosis-factor a; VAS, visual
analogue scale.
Wang et al. Arthritis Research & Therapy 2010, 12:R185
http://arthritis-research.com/content/12/5/R185
Page 8 of 11that of the cLBP group was never significantly below
that of the German reference group. After six months
the MCS value in the cLBP+DE group was almost iden-
tical with that of the cLBP group, only slightly below it,
which also speaks for the long-term effect of multimodal
therapy with regard to improvement in mental health.
Potential confounding factors for TNF-a serum levels
were analysed in this study. For many clinical para-
meters such as age, sex, BMI, sleep duration, exercise
activity, pain intensity, physical composite scores were
comparable between patients of both groups. Age, sex,
BMI, CES-D score and back function did not correlate
with TNF-a serum level. The single correlation between
TNF-a serum level and pain during the previous week
was found at T3 in the comorbid group but not in the
cLBP group without depression. The fact that at the end
of the study a higher proportion of the formerly depres-
sive cLBP patients reported alcohol and nicotine
c o n s u m p t i o ni nt h ep r e v i o us 24 hours (Table 2) seems
not to be relevant for TNF-a level, pain intensity and
severity of depression, because none of these parameters
differed between patients with and without depression
at T3 after adjustment by Bonferroni-correction.
The influence of medication on TNF-a serum level
was also studied. It is known that tricyclic antidepres-
sants could lower the production of pro-inflammatory
cytokines like TNF-a, IL-1ß and IFN-r [47-49]. And
improvement of symptoms regarding depression by
cytokines was caused by the inhibition of production of
pro-inflammatory cytokines and elevation of anti-inflam-
matory cytokines [50]. NSAIDs may inhibit the enzyme
COX-1 and COX-2, and therefore, reduce the serum
level of IL-6, NO and cortisone [51,52]. Even opioids
influence the cytokine production and shift to a increas-
ing of anti-inflammatory reaction [53,54]. In the current
s t u d y ,t h e r ew a sn od i f f e r e n c ei nt h eu s eo fa n t i d e p r e s -
sants and opioids between patients with and without
depressive symptoms. We found a negative correlation
between TNF-a serum level and analgesic intake at the
beginning of the study in the cLBP+DE group and a
positive correlation between TNF-a serum level and
NSAIDs at the end of the study in the cLBP group.
A possible explanation for the decline of TNF-a
serum levels is that patients with comorbid depression
took significantly more NSAIDs at T0 (28%) than
patients with cLBP alone (7%) and used these drugs sig-
nificantly less at T3 (7%) than at T0. NSAIDs are able
to inhibit TNF-a production and TNF-a serum level at
T0 was similarly high in both groups although NSAIDs
intake in comorbid group was significantly greater at
T 0 .S oi ti sp o s s i b l et h a tt h eT N F - a serum level was
higher in the comorbid group and reduced by NSAIDs
intake at T0. But there is no correlation between
NSAIDs and TNF-a in cLBP+DE group. In the course
of the study TNF-a serum levels of boths groups were
significantly lowered from T0 to T3 without a distinc-
tion to the level healthy controls at T3. In summary
regarding TNF-a we suggest that multidisciplinary pain
therapy may be responsible for the normalisation of its
level without an impact of medication.
One primary limitation of our study is the small sample
size. Therefore, the results from this study should be
further confirmed in a larger collective. However, our
study addresses for the first time a timely topic regarding
the shared biological underpinnings of pain and depres-
sion, and it employs longitudinal methodology. Our results
indicate therapeutic options that target both pain and
depressive disorders including cognitive behavioral ther-
apy, exercise, and pharmacotherapy. Future research is
needed to further clarify the multiple interactions of pain
and depressive disorders, including effects on neurohor-
monal-cytokine interaction, which will aid in the develop-
ment of more effective treatment strategies addressing all
symptoms with which a patient might present.
Conclusions
The findings of this study suggest that depression as a
comorbidity to cLBP did not influence the serum TNF-
a level during six months’ follow-up, but did affect the
success of therapy. cLBP patients with comorbid depres-
sion benefited more strongly from multidisciplinary pain
therapy than cLBP patients without depression. We
assume that one or more elements of the therapy
(whether psychotherapy, physical therapy, physiotherapy
or others) may improve subjective pain perception,
mood and immune function (in this case, TNF-a serum
level). However, this needs to be confirmed in a further
study involving a larger collective.
Abbreviations
ATC: Anatomical Therapeutic Chemical Classification; CBT: cognitive
behavioural treatment; CES-D: German version of Centre for Epidemiological
Studies Depression Scale; ICD-10: International Statistical Classification of
Diseases and Related Health Problems: 10
th Revision; IL: interleukin; MCS:
Mental Composite Scale; MDD: major depressive disorder; MDPT:
multidisciplinary pain therapy; NSAIDs: non-steroidal anti-inflammatory drugs;
PCS: Physical Composite Scale; SF-36: 36-item short form health survey; TNF-
a: tumour necrosis factor alpha.
Acknowledgements
This work was funded by a research grant from the Orthopaedic University
hospital, University of Heidelberg, Germany. We would like to thank Dr.
Dorothee Mangini-Guidano for the support of blood collection.
Author details
1University of Heidelberg, Department of Orthopaedic Surgery, Schlierbacher
Landstrasse 200a, 69118 Heidelberg, Germany.
2University of Marburg,
Department of Clinical Psychology and Psychotherapy, Gutenbergstrasse 18,
35032 Marburg, Germany.
Authors’ contributions
HW conceived the hypothesis for the manuscript, participated in data
collection, wrote the first draft of the manuscript and had primary
Wang et al. Arthritis Research & Therapy 2010, 12:R185
http://arthritis-research.com/content/12/5/R185
Page 9 of 11responsibility for the manuscript process. CA participated in data collection,
performed the statistical analyses, contributed to and approved the final
manuscript. WR participated in the interpretation of data, and contributed to
and approved the final manuscript. MS conceived the study and participated
in its design and helped to draft the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 April 2010 Revised: 26 August 2010
Accepted: 11 October 2010 Published: 11 October 2010
References
1. Grabow TS, Christo PJ, Raja SN: Complex regional pain syndrome:
diagnostic controversies, psychological dysfunction, and emerging
concept. In Pain and Depression, an Interdisciplinary Patient Centered
Approach. Edited by: Clark MR, Treisman GJ. Basel; Freiburg [u.a.]: Karger;
2004:25:89-102.
2. Fishbain DA: Approaches to treatment decisions for psychiatric
comorbidity in the management of the chronic pain patient. Med Clin
North Am 1999, 83:737-760, vii.
3. Patten SB: Long-term medical conditions and major depression in a
Canadian population study at waves 1 and 2. J Affect Disord 2001,
63:35-41.
4. Campbell LC, Clauw DJ, Keefe FJ: Persistent pain and depression: a
biopsychosocial perspective. Biol Psychiatry 2003, 54:399-409.
5. Ohayon MM, Schatzberg AF: Using chronic pain to predict depressive
morbidity in the general population. Arch Gen Psychiatry 2003, 60:39-47.
6. Haythornthwaite JA, Sieber WJ, Kerns RD: Depression and the chronic pain
experience. Pain 1991, 46:177-184.
7. Weickgenant AL, Slater MA, Patterson TL, Atkinson JH, Grant I, Garfin SR:
Coping activities in chronic low back pain: relationship with depression.
Pain 1993, 53:95-103.
8. Kendall NAS, Linton SJ, Main CJ: Guide to assessing psychosocial yellow
flags in acute low back pain: risk factors for long-term disability and
work loss. Wellington: Accident and Rehabilitation & Compensation Insurance
Corporation of New Zealand and the National Health Committee 1997.
9. Ericsson M, Poston WS, Linder J, Taylor JE, Haddock CK, Foreyt JP:
Depression predicts disability in long-term chronic pain patients. Disabil
Rehabil 2002, 24:334-340.
10. Fisher BJ, Haythornthwaite JA, Heinberg LJ, Clark M, Reed J: Suicidal intent
in patients with chronic pain. Pain 2001, 89:199-206.
11. Sheehan DV: Establishing the real cost of depression. Manag Care 2002,
11:7-10, discussion 21-15.
12. Greenberg PE, Birnbaum HG: The economic burden of depression in the
US: societal and patient perspectives. Expert Opin Pharmacother 2005,
6:369-376.
13. Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain
comorbidity: a literature review. Arch Intern Med 2003, 163:2433-2445.
14. Airaksinen E, Wahlin A, Larsson M, Forsell Y: Cognitive and social
functioning in recovery from depression: results from a population-
based three-year follow-up. J Affect Disord 2006, 96:107-110.
15. Pfingsten M, Schops P: [Low back pain: from symptom to chronic
disease]. Z Orthop Ihre Grenzgeb 2004, 142:146-152.
16. Poleshuck EL, Bair MJ, Kroenke K, Damush TM, Tu W, Wu J, Krebs EE,
Giles DE: Psychosocial stress and anxiety in musculoskeletal pain
patients with and without depression. Gen Hosp Psychiatry 2009,
31:116-122.
17. Schiltenwolf M: [Assessment of musculoskeletal pain]. Z Rheumatol 2007,
66:473-483.
18. Kröner-Herwig B, Frettlöh J: Behandlung chronischer Schmerzsyndrome:
Plädoyer für einen multiprofessionellen Therapieansatz. In Psychologische
Schmerztherapie; Grundlagen, Diagnostik, Krankheitsbilder, Schmerz-
Psychotherapie. Edited by: Basler H-D, Franz C, Kröner-Herwig B, Rehfisch H-
P. Berlin; Heidelberg [u.a.]: Springer; , 5. Aufl 2004:499-524.
19. Wang H, Moser M, Schiltenwolf M, Buchner M: Circulating cytokine levels
compared to pain in patients with fibromyalgia - a prospective
longitudinal study over 6 months. J Rheumatol 2008, 35:1366-1370.
20. Schiltenwolf M, Buchner M, Heindl B, von Reumont J, Muller A, Eich W:
Comparison of a biopsychosocial therapy (BT) with a conventional
biomedical therapy (MT) of subacute low back pain in the first episode
of sick leave: a randomized controlled trial. Eur Spine J 2006,
15:1083-1092.
21. Buchner M, Zahlten-Hinguranage A, Schiltenwolf M, Neubauer E: Therapy
outcome after multidisciplinary treatment for chronic neck and chronic
low back pain: a prospective clinical study in 365 patients. Scand J
Rheumatol 2006, 35:363-367.
22. Wang H, Schiltenwolf M, Buchner M: The role of TNF-alpha in patients
with chronic low back pain-a prospective comparative longitudinal
study. Clin J Pain 2008, 24:273-278.
23. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. Ann
Rheum Dis 1957, 16:494-502.
24. Roland M, Morris R: A study of the natural history of back pain. Part I:
development of a reliable and sensitive measure of disability in low-
back pain. Spine (Phila Pa 1976) 1983, 8:141-144.
25. Hautzinger M, Bailer M: Allgemeine Depressions Skala. Weinheim: Beltz
1993.
26. Klein T, Magerl W, Hopf HC, Sandkuhler J, Treede RD: Perceptual correlates
of nociceptive long-term potentiation and long-term depression in
humans. J Neurosci 2004, 24:964-971.
27. Deak T, Bellamy C, D’Agostino LG, Rosanoff M, McElderry NK, Bordner KA:
Behavioral responses during the forced swim test are not affected by
anti-inflammatory agents or acute illness induced by lipopolysaccharide.
Behav Brain Res 2005, 160:125-134.
28. Robinson MJ, Edwards SE, Iyengar S, Bymaster F, Clark M, Katon W:
Depression and pain. Front Biosci 2009, 14:5031-5051.
29. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J:
Serotonin 5-HT2 receptor imaging in major depression: focal changes in
orbito-insular cortex. Br J Psychiatry 1997, 171:444-448.
30. Frot M, Mauguiere F: Dual representation of pain in the operculo-insular
cortex in humans. Brain 2003, 126:438-450.
31. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK: Human brain
mechanisms of pain perception and regulation in health and disease.
Eur J Pain 2005, 9:463-484.
32. Mondal S, Sharma VK, Das S, Goswami U, Gandhi A: Neuro-cognitive
functions in patients of major depression. Indian J Physiol Pharmacol
2007, 51:69-75.
33. Alexopoulos GS, Gunning-Dixon FM, Latoussakis V, Kanellopoulos D,
Murphy CF: Anterior cingulate dysfunction in geriatric depression. Int J
Geriatr Psychiatry 2008, 23:347-355.
34. Honda T, Maruta T, Takahashi K: Brain perfusion abnormality in patients
with chronic pain. Keio J Med 2007, 56:48-52.
35. Bingel U, Quante M, Knab R, Bromm B, Weiller C, Buchel C: Subcortical
structures involved in pain processing: evidence from single-trial fMRI.
Pain 2002, 99:313-321.
36. Lange JH: Endotoxin as a factor for joint pain and rheumatoid arthritis.
Clin Rheumatol 2004, 23:566, author reply 567.
37. MacMaster FP, El-Sheikh R, Upadhyaya AR, Nutche J, Rosenberg DR,
Keshavan M: Effect of antipsychotics on pituitary gland volume in
treatment-naive first-episode schizophrenia: a pilot study. Schizophr Res
2007, 92:207-210.
38. Ortega E: Neuroendocrine mediators in the modulation of phagocytosis
by exercise: physiological implications. Exerc Immunol Rev 2003, 9:70-93.
39. Ortega E, Giraldo E, Hinchado MD, Martin L, Garcia JJ, De la Fuente M:
Neuroimmunomodulation during exercise: role of catecholamines as
‘stress mediator’ and/or ‘danger signal’ for the innate immune response.
Neuroimmunomodulation 2007, 14:206-212.
40. Koch A, Zacharowski K, Boehm O, Stevens M, Lipfert P, von Giesen HJ,
Wolf A, Freynhagen R: Nitric oxide and pro-inflammatory cytokines
correlate with pain intensity in chronic pain patients. Inflamm Res 2007,
56:32-37.
41. Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and
recurrence in unipolar depression: a comparative meta-analysis of
cognitive-behavioral therapy’s effects. J Consult Clin Psychol 2007,
75:475-488.
42. Chou R, Huffman LH: Medications for acute and chronic low back pain: a
review of the evidence for an American Pain Society/American College
of Physicians clinical practice guideline. Ann Intern Med 2007, 147:
505-514.
43. Chou R, Huffman LH: Nonpharmacologic therapies for acute and chronic
low back pain: a review of the evidence for an American Pain Society/
Wang et al. Arthritis Research & Therapy 2010, 12:R185
http://arthritis-research.com/content/12/5/R185
Page 10 of 11American College of Physicians clinical practice guideline. Ann Intern Med
2007, 147:492-504.
44. Bannan N: Multimodal therapy of treatment resistant depression: a study
and analysis. Int J Psychiatry Med 2005, 35:27-39.
45. Molton IR, Graham C, Stoelb BL, Jensen MP: Current psychological
approaches to the management of chronic pain. Curr Opin Anaesthesiol
2007, 20:485-489.
46. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD: Meta-analysis of
psychological interventions for chronic low back pain. Health Psychol
2007, 26:1-9.
47. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE: Differential effect of
chronic antidepressant treatments on lipopolysaccharide-induced
depressive-like behavioural symptoms in the rat. Life Sci 1999,
65:1773-1786.
48. Connor TJ, Harkin A, Kelly JP, Leonard BE: Olfactory bulbectomy provokes
a suppression of interleukin-1beta and tumour necrosis factor-alpha
production in response to an in vivo challenge with lipopolysaccharide:
effect of chronic desipramine treatment. Neuroimmunomodulation 2000,
7:27-35.
49. Kubera M, Holan V, Mathison R, Maes M: The effect of repeated
amitriptyline and desipramine administration on cytokine release in
C57BL/6 mice. Psychoneuroendocrinology 2000, 25:785-797.
50. Castanon N, Leonard BE, Neveu PJ, Yirmiya R: Effects of antidepressants
on cytokine production and actions. Brain Behav Immun 2002, 16:569-574.
51. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID
lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide
synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm
Res 1999, 48:369-379.
52. Strouse TB: The relationship between cytokines and pain/depression: a
review and current status. Curr Pain Headache Rep 2007, 11:98-103.
53. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR,
Ambrosch A, Konig W, Hollt V: Regulation of mu-opioid receptor gene
transcription by interleukin-4 and influence of an allelic variation within
a STAT6 transcription factor binding site. J Biol Chem 2001,
276:43901-43908.
54. Borner C, Woltje M, Hollt V, Kraus J: STAT6 transcription factor binding
sites with mismatches within the canonical 5’-TTC...GAA-3’ motif
involved in regulation of delta- and mu-opioid receptors. J Neurochem
2004, 91:1493-1500.
doi:10.1186/ar3155
Cite this article as: Wang et al.: Influence of comorbidity with
depression on interdisciplinary therapy: outcomes in patients with
chronic low back pain. Arthritis Research & Therapy 2010 12:R185.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wang et al. Arthritis Research & Therapy 2010, 12:R185
http://arthritis-research.com/content/12/5/R185
Page 11 of 11